Daiichi Sankyo names Ken Keller chief commercialization officer, effective April 2027

• Daiichi Sankyo named Ken Keller chief commercialization officer, effective April 1, 2027, to run a new globally integrated Commercialization Unit.
• Keller joined in 2014, led Global Oncology Business for five years, previously spent 20 years at Amgen, later served as Spectrum Pharmaceuticals COO.
• The overhaul centralizes commercialization into five regional businesses to speed decisions, tighten coordination, optimize investment, targeting 20 new indications by 2030.
• Regional leadership changes include Yuichi Yomasu for China, Markus Kosch for Europe, Nobuo Murakami for Japan, Asia and Pacific.
• Global function appointments include Oliver Appelhans for commercial excellence, Radha Ramkumar for oncology alliance management, Dan Switzer for marketing, access and pricing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608240300BIZWIRE_USPR_____20260823_BW786995) on August 24, 2026, and is solely responsible for the information contained therein.